Renal & Urology News

Assessing Recurrence Risk in Patients With Non-Clear Cell Renal Cell Carcinoma

In risk groups defined by American Urologic Association criteria, recurrences were reported in 8.9% of patients of the low-risk group, 11% of patients in the intermediate-risk group, 22% of those in ...
Renal & Urology News

Recurrent Non-Muscle Invasive Bladder Cancer Often Matches Primary Disease

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...
Seeking Alpha

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial

Adding one year of IMFINZI treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone WILMINGTON, Del.-- ...
The Motley Fool

Non-QM Loan: Overview, Pros and Cons, Example

Non-qualified mortgages cater to those with nontraditional incomes or credit issues. These mortgages may offer lower initial payments but carry higher long-term costs. Non-QM loans don't meet CFPB ...
BioSpace

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade ...

24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE ...
Seeking Alpha

XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
MedPage Today

Non-Surgical Option Approved for Recurrent Low-Grade Bladder Cancer

The FDA approved mitomycin intravesical solution (Zusduri) as a nonsurgical option for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). The product won the indication ...
Business Wire

UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty ...
Business Wire

UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen (NASDAQ: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced ...
News 6 WKMG

What are non-arrest cases? Examples like these prompted new state attorney policy

Read full article: ‘Help! I’m shot:’ New video shows gunman wounding 2 Orlando police officers Sterns accused of killing 13-year-old Madeline Soto Read full article: ‘We are in a crisis:’ Budget cuts ...
ascopubs.org

Preoperative Maximum Standardized Uptake Value Emphasized in Explainable Machine Learning Model for Predicting the Risk of Recurrence in Resected Non–Small Cell Lung Cancer

This retrospective study included 643 patients who had undergone NSCLC resection. ML models (random forest, gradient boosting, extreme gradient boosting, and AdaBoost) and a random survival forest ...